Abstract
Background Long-term disability after stroke is standardly assessed 3 months post-onset, using the modified Rankin Scale (mRS). The value of an early, day 4 mRS assessment for projecting the 3-month disability outcome has not been formally investigated.
Methods In this cohort of patients with acute cerebral ischemia and intracranial hemorrhage, we analyzed day 4 and day 90 mRS assessments in the NIH Field Administration of Stroke Therapy– Magnesium (FAST-MAG) Phase 3 trial. The performance of day 4 mRS, alone and as part of multivariate models, in predicting day 90 mRS was assessed using correlation coefficients, percent agreement, and the kappa statistics.
Results Among the 1573 acute cerebrovascular disease (ACVD) patients, 1206 (76.7%) had acute cerebral ischemia (ACI), while 367 (23.3%) had intracranial hemorrhage. Among all 1573 ACVD patients, day 4 mRS and day 90 mRS correlated strongly, Spearman’s rho=0.79, in unadjusted analysis with weighted kappa of 0.59. For dichotomized outcomes, simple carry-forward of the day 4 mRS performed fairly well in agreeing with day 90 mRS: mRS 0-1 (k=0.67), 85.4%; mRS 0-2 (k=0.59), 79.5%; fatal outcome, 88.3% (k=0.33). Correlations of 4d and 90d mRS were stronger for ACI than ICH patients, 0.76 vs 0.71.
Conclusions In this acute cerebrovascular disease patient cohort, assessment of global disability performed on day 4 is highly informative regarding long-term, 3-month mRS disability outcome, alone, and even more strongly in combination with baseline prognostic variables. The day 4 mRS is a useful measure for imputing the final patient disability outcome in clinical trials and quality improvement programs.
Competing Interest Statement
JLS is consultant on clinical trial design to BrainQ.
Clinical Trial
NCT00059332
Funding Statement
The original clinical trial study was supported by a Research Project Cooperative Agreement award (U01 NS44364) from the National Institute of Neurological Disorders and Stroke.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This was a secondary analysis of patients enrolled in the National Institute of Health Field Administration of Stroke Therapy Magnesium (FAST-MAG) Trial. The institutional review boards of each hospital approved trial performance.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Shayandokht Taleb, MD Email: talebshayandokht{at}gmail.com, Jenny Ji-hyun Lee, MD Email: Jennyjlee{at}mednet.ucla.edu, Samuel Asanad, MD Email: sasanad{at}som.umaryland.edu, Sidney Starkman, MD Email: starkman{at}mednet.ucla.edu, Scott Hamilton Email: scott.hamilton{at}signanthealth.com, Robin A. Conwit, MD Email:robinconwit{at}hotmail.com, Nerses Sanossian MD Email: nsanossi{at}usc.edu, Jeffrey L Saver, MD Email: jsaver{at}mednet.ucla.edu
Data Availability
The datasets generated and/or analyzed during the current study are available in the ClinicaTrials.gov repository, https://clinicaltrials.gov/ct2/show/NCT00059332.
